Member Info for JimiHendrix

Technical traders have come to call a long-bodied candle with no upper or lower shadow a marubozo, which is Japanese for "close-cropped."

When this type of candle is found in an uptrend, it is used to signal that the bulls are aggressively buying the asset and it suggests that the momentum may continue upward. The bullish marubozo candle (open equals low, high equals close) can signal a reversal when it is found at the end of a downtrend because it shows that the sentiment has changed and that the bulls are likely to continue pushing the asset higher.

....

The last time we had one of these was 26th November and the next day it went up 100%.

I think they are prioritising certain types of tests, as there weren't any LFT tests approved the last time I looked.

Seems to be causing a nice bounce back in the markets today.

Short, medium and long term holders are all essential.

Most of us already know most of what is in the article yes (it's why many of us have bought shares) but the wider market doesn't know, things will start to turn around here very soon and articles like that do a great job of spreading the word. It's almost 3 months when the shareprice was at this price and then it went up 400% over a few days, and now we have AIHL about to be unleashed through the NHS, potential POC European sales, CTDA imminent, and a full-time sales team on the case.

There’s a great article on Genedrive here…

https://finance.yahoo.com/news/market-sentiment-around-loss-making-060430641.html

Genedrive plc (LON:GDR) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. genedrive plc, a molecular diagnostics company, engages in developing and commercializing point of need diagnostics platform for infectious diseases, genotyping, pathogen detection, and other indications. On 30 June 2021, the UK£15m market-cap company posted a loss of UK£691k for its most recent financial year. Many investors are wondering about the rate at which genedrive will turn a profit, with the big question being “when will the company breakeven?” We've put together a brief outline of industry analyst expectations for the company, its year of breakeven and its implied growth rate.

Check out our latest analysis for genedrive

Expectations from some of the British Life Sciences analysts is that genedrive is on the verge of breakeven.

https://simplywall.st/stocks/gb/pharmaceuticals-biotech/aim-gdr/genedrive-shares

We were only expensive for the Indian market, and that's because they imposed the price cap.

Great info Starres. I'm feeling very confident about both AIHL and POC.

Baring in mind the NHS have part developed AIHL (in fact it was their idea – it is something they needed), it will get written in to guidelines without delay. There is no question really.

Budd said that there was a good chance AIHL will get written into NHS guidelinesby NICE well before the time period the company has given. I'm suspecting March, going by the tweets of exciting few weeks ahead. If that happens it will obviously increase the projected AIHL profits for this year.

From an article last week about the Optigene Covid POC test (which isn't as good as Genedrive's)... great to see how enthusiastic the medical professionals are about increasing the use of POC tests in humans, similar to how they have been used by vets for years.

....

"For RNA RT-LAMP on swabs, the overall diagnostic sensitivity was as high as RT-qPCR testing. This supports the use of such testing in mobile testing units, as recently undertaken for testing of individuals from overseas attending high level meetings in the UK.

For Direct RT-LAMP, the overall diagnostic sensitivity was highest (85%) on saliva samples, with a specificity of 100% when compared to standard RT-qPCR testing. In tests on saliva samples containing a high viral load, the sensitivity of the test increased to 99%. This indicates that the test is highly effective in identifying infectious cases, including from people not displaying symptoms.

The findings demonstrate that RT-LAMP is applicable to a variety of use-cases, including frequent, interval-based testing of saliva with Direct RT-LAMP from asymptomatic individuals that may otherwise be missed using symptomatic testing alone.

Dr Veronica Fowler, a virologist who specialises in molecular detection methods and pioneered the optimisation and validation of the RT-LAMP technology for COVID-testing said:

“Many of the country’s leading molecular scientists and virologists have joined together to rigorously evaluate the Optigene RT-LAMP test in a variety of settings and confirmed its high accuracy in individuals with and without symptoms. The test is particularly effective in identifying people who are at risk of transmitting the infection to others, including people not displaying symptoms. Despite the emergence of a number of highly mutated variants, including Omicron, the RT-LAMP assay continues to perform with high accuracy due to particular features of how the test was developed.

“The application of using lower cost, rapid molecular tests, such as RT-LAMP to identify and control highly infectious viral diseases has been performed in the veterinary world for years. I am pleased through this huge collaborative effort that we have succeeded in transferring this concept and practice within the human infectious disease world for the benefit of saving people’s lives.”

Professor Keith Godfrey, of the University of Southampton MRC Lifecourse Epidemiology Centre and NIHR Southampton Biomedical Research Centre, who led the community based aspects of the evaluation said:

“It is extremely helpful to have the ‘real world’ demonstration of how the RT-LAMP test can be implemented in different settings. It provides an important example of how these tests can make a valuable contribution to overall COVID-19 testing capability.”

There are numerous Covid-19 mobile test units equipped with inferior POC Lamp tests. These will have some competition from Genedrive once they receive CTDA (the company is currently aggressively chasing this).

RNS - Placing sounds likely

I believe we are on the verge of some very positive AIHL news, John wouldn't have tweeted about a very exciting next few weeks if not. We know anyway from RNS's what is expected in the AIHL front this quarter so it seems things are going to plan.

POC very exciting too, it seems they have a industry leading product ready and well timed for the POC market as things move away from mass testing. I wouldn't sell at this price, I do wish I had sold at 21 though in hindsight of course as I always thought it might drop back to 17p before a proper reversal.

For Hashtag…

Care home bosses are now calling for rapid PCR tests — which are as accurate as a a standard PCR and don't need to be sent to a lab — to be rolled out nationwide.

They work by putting swabs into a machine that gives results within half an hour — but they are still being trialled in the NHS and can cost up to £20,000 per device.

The devices are designed for use by people with no clinical training and have already been rolled out in some private hospitals.

Also isolation is not coming to an end, it just won’t be a legal requirement. The market Genedrive are targeting will most certainly be isolating, and testing in care homes and hospitals will never go away.

*risking :)

*Their

No Bojo's isn't saying that at all, he's saying it will no longer be a legal requirement to isolate. They're guidance will be to isolate and not go in to work if you have Covid. Full details of the new guidance will follow in a few weeks time but for sure they are recommending people isolate.

That's generally and in situations like care homes and hospitals nobody will be ricking bringing Covid in to work.

Care home bosses are now calling for rapid PCR tests — which are as accurate as a a standard PCR and don't need to be sent to a lab — to be rolled out nationwide...

Care bosses have called for rapid point-of-care Covid tests to be brought into retirement homes to slash the number of staff isolating unnecessarily.

Current rules in England mean any staff member who tests positive on a lateral flow has to isolate at home until the result is confirmed by a PCR — which can take up to four days, according to an industry survey.

Some 11,000 staff were absent with Covid last month and experts say the move to ditch visitor limits will inevitably allow the virus to keep circulating in homes.

Care home bosses are now calling for rapid PCR tests — which are as accurate as a a standard PCR and don't need to be sent to a lab — to be rolled out nationwide.

They work by putting swabs into a machine that gives results within half an hour — but they are still being trialled in the NHS and can cost up to £20,000 per device.

The devices are designed for use by people with no clinical training and have already been rolled out in some private hospitals.

The survey by medtech firm QuantuMDx of nearly 100 homes in the UK found 86 per cent of managers, owners and employees said they would be in favour of bringing in the machines.

And three quarters said current PCR wait times for staff are leading to vulnerable residents suffering unnecessarily.

Mike Padgham, chair of the Independent Care Group (ICG), said any new way to cut down isolation times 'would be worth its weight in gold'.

https://www.dailymail.co.uk/news/article-10467937/Care-bosses-call-rapid-PCR-style-Covid-tests-brought-homes.html